Assembly Biosciences (ASMB) 2025 Conference June 04, 2025 08:45 AM ET Speaker0 Good morning everyone. Welcome to the Jefferies Healthcare Conference. My name is Anthea Lee, part of the Healthcare Research Team here at Jefferies. We're very fortunate to have Assembly Biosciences with us today. We have Jason Okazaki, CEO, and CMO Anuj Ghajar. Welcome. For those that are new to the story, perhaps we just start with a quick overview of the company, the pipeline and key catalysts that you see coming up for the r ...

Group 1 - Occidental Petroleum Corporation (NYSE: OXY) is the largest operator in the Permian Basin, a crucial area for shale oil production in the US [1] - The company has a significant international presence and operations [1] Group 2 - The article expresses a beneficial long position in the shares of OXY through stock ownership, options, or other derivatives [2]

商品期权操作灵活，运用在套保上也较为广泛，可在实际操作过程中却发现，部位该买还是该卖、合约月份和行 权价如何选择、应该套保多大规模等，需要具体问题具体对待。本文将就这些实际问题进行解答。 A 部位的组合原则 期权套保有各种不同的策略，比如期货+期权套保、海鸥套保等策略，看起来部位很多，操作很复杂，许多套保 者刚开始使用时，不知道如何组合部位。其实，所有的期权策略都是由四个部位组成的：买进看涨、买进看跌、卖出 看涨、卖出看跌，只要记住各种部位的功能，再根据实际需求把部位组合起来就行了，并没有那么复杂。 表为期权各个部位的特性与功能 期权策略有四个基本部位，其又可以简化为买与卖两种。 买方部位具有获利可以跟随行情持续增加的特点，其在套保方面的表现较为突出。套保者想把损失控制在什么点 位，就买进那个点位行权价的期权。卖方部位拥有权利金收入，其在降低成本方面的表现较为突出。套保者认为标的 的价格不会到达某个点位，就卖出那个点位行权价的期权。 表为买方部位和卖方部位的对比 简单来说，买方部位的功能就是用一些权利金支出，换取可能的获利放大机会，获利就可对冲现货的不利情形； 卖方部位的功能就是把一些行情可能到不了的地方，换 ...

Corporate Highlights and Recent Developments Expanded Pipeline with INB-600 Gamma-Delta T Cell Engager Platform Demonstrated Additional Clinical Progress Across Gamma-Delta T Cell Therapy Pipeline NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today reported financial results and business highlights for the first quarter ended March 31, 2025 and recent corporate highlights. "IN8bio stands ...

前面我们讲了这么多关于期权的知识，那个人投资者能参与期权交易吗？答案当然是肯定的，但个人投资者的参与有一定门槛。可以简单概括 为"五有一无"，即有资产、有经历、有知识、有经验、有风险承受能力和无违法违规行为。 个人投资者开通期权的"五有一无"条件详解 （一）有资产 申请开户前 20 个交易日日均托管在其委托的期权经营机构的证券市值与资金账户可用余额（不含通过融资融券交易融入的证券和资金），合 计不低于人民币 50 万元。 例如，小李在申请开户前 20 个交易日，其股票账户中的股票市值加上资金账户中的可用现金，平均每天都达到了 50 万元以上，才满足这一条 件。 投资者需要具备期权基础知识，并通过交易所认可的相关测试。期权涉及到诸多专业概念，如行权价、权利金、隐含波动率、Delta、Gamma 等。 只有理解这些概念和期权交易的基本原理、策略，投资者才能在交易中做出明智的决策。 分级考试：分为一级、二级、三级，逐级递进，涵盖期权基础、交易策略、风险控制等内容。 综合考试：一次性覆盖三级内容，总分100分，70分及格，考试时间30分钟。 （四）有模拟交易经历 具有交易所认可的期权模拟交易经历也是开户的必要条件之一 ...

NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies for cancer and autoimmune diseases, today announced new preclinical data from its innovative γδ T cell engager (γδ-TCE) platform. The data will be presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting on April 30, 2025. The data showed that IN8bio's new γδ-TCE platform demonstrated potent and consistent can ...

Leiden, the Netherlands, April 25, 2025: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) announces the following presentations by the Company or its collaborators at the 2025 Annual Meeting of the Clinical Immunology Society (CIS), taking place May 1-4, 2025 in Philadelphia, PA. These presentations include Phase III clinical data for leniolisib for pediatric patients aged 4-11 years with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) and insights into APDS and additional p ...

Proven 20-year career in drug discovery and development track record leading to 12 pre-clinical/clinical candidates and 7 investigational new drug / clinical trial applicationsExtensive knowledge in the biochemistry and pharmacology of the Delta Opioid Receptor (DOR), the primary target in TuHURA's Antibody Drug Conjugate (ADC) and Antibody Peptide Conjugate (APC) technology platformInventor of first-in-class spirocyclic DOR agonists as potential analgesics; clinical- stage products licensed to PfizerLed th ...